About BioxyTran Inc.


Bioxytran, Inc. is a biopharmaceutical company whose mission is to develop anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia.The company focuses on the development and commercialization of first-in-class treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The Company’s lead product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. It will be tested as a potent resuscitative agent to treat Ischemic brain strokes, also known as Cardiac Cerebrovascular Accidents (CVA). In addition, our drug candidate, BXT-252, will be tested as a regenerative agent in a variety of wound healing applications.Bioxytran, Inc. is working to develop new molecules that address unmet medical needs. Bioxytran, Inc.’s drug candidates have a large market potential as anti-necrotic drugs for multiple disease indications that result from hypoxia.


BTX-25 is a glyco-polymer made of hybrid molecules of HEME chemical structure taken from the Hemoglobin molecule and a proprietary polymer chemical structure. Intravenously administered, it behaves as a theraputic to deliver oxygen to tissues in the body.  5000 times smaller in molecular size compared to red blood cells, the BTX-25 glyco-polymer can penetrate the area in the brain blocked by a clot and oxygenate the part of the brain failing to receive sufficient oxygen. A single red blood cell (RBC) contains almost 300 million hemoglobin molecules, each of which can carry 4 oxygen molecules. A hemoglobin molecule consists of protein and iron (Fe) which give the blood cell its red color. When blood passes through the lungs, oxygen binds to the BTX-25 glycoprotein the same as it would to an RBC, and as the infused blood passes through the tissue capillaries, oxygen is released. The hemoglobin will not release the oxygen into tissue if too much oxygen is already present. Oxygen delivery to tissue and organs is a critical treatment issue in a number of medical situations that are suitable for BTX-25 including stroke conditions.



BioXyTran Inc.’s drug BXT-25 is designed to oxygenate ischemic (reduced blood flow) regions in the brain that suffered from hypoxia during a brain stroke. To minimize irreversible damage to the brain, it may be administered prior during and after current available treatments such as rt-PA to dissolve the clot and to have a positive confounding effect by keeping the brain oxygenated. The glycoprotein drug BXT-25 is a modified hemoglobin structure, bound to a proprietary co-polymer chemical structure. This new chemical structure offers significant improvement because there is no treatment to deliver oxygen prior to removing the blockage (clot) by rTPA or surgery. BXT-25’s co-polymer proprietary chemical structure acts as the main carrier of oxygen, instead of the Red Blood Cell which are blocked by the clot. BXT-25 construct substantially reduces methemoglobin formation and nitric oxide scavenging that may contribute to a variety of disorders—such as renal failure, vasoconstriction, hypertension, myocardial infarction, and related toxicity issues.Furthermore, BXT-25’s small size, roughly 1/5,000th that of a red blood cell, enables it to perfuse constricted, ischemic capillaries that are inaccessible to red blood cells due to clots or other obstructions. The new molecule is stable in solution for 3 years at 250°C. and can be freeze-dried (lyophilized) for an even longer shelf life.


BioXyTran Inc.’s drug BXT-252 is designed to treat chronic wounds resulting from ischemia caused by occlusion of capillaries. BXT-252 has the same modality and physical properties as BXT-25; however, its proprietary co-polymer can improve the healing of pressure and arterial ulcers. BXT-252 is also a modified hemoglobin structure. Its size, roughly 1/5,000th that of a red blood cell, enables it to perfuse constricted, ischemic capillaries, which are inaccessible to red blood cells due to ischemia conditions or other obstructions of the blood flow.

Learn About Stroke and Ischemia


Stroke, also known as cerebrovascular accident (CVA), or brain attack, is when poor blood flow to the brain results in necrosis and cell death. Stroke is the second most frequent cause of death worldwide. South Asians are at particularly high risk for stroke, accounting for 40% of global stroke deaths.

There are two main types of stroke: ischemic and hemorrhagic. Ischemic strokes are caused by interruption of the blood supply to the brain, while hemorrhagic strokes result from the rupture of a blood vessel or an abnormal vascular structure. Most of the strokes are ischemic, the rest being hemorrhagic. Bleeding can develop inside areas of ischemia, a condition known as hemorrhagic transformation.

Brain tissue ceases to function if deprived of oxygen for more than 60 to 90 seconds, and after approximately three hours will suffer irreversible injury possibly leading to death of the tissue or necrosis. Since blood vessels in the brain are now blocked, the brain becomes low in energy, and thus it resorts into using anaerobic metabolism within the region of brain tissue affected by ischemia.

In addition to damaging effects on brain cells, ischemia and infarction can result in loss of structural integrity of brain tissue and blood vessels The loss of vascular structural integrity results in a breakdown of the protective blood brain barrier that contributes to cerebral edema, which can cause secondary progression of the brain injury.

Brain ischemia causes insufficient blood flow to the brain, and can be acute or chronic. Acute ischemic stroke is a neurological emergency that may be reversed if treated rapidly. Chronic ischemia of the brain may result in a form of dementia called vascular dementia. A brief episode of ischemia affecting the brain is called a transient ischemic attack, often erroneously referred to as a “mini-stroke” (1).

(1) “Thrombus”. MedlinePlus. U.S. National Library of Medicine

Wound Healing

Wound healing is the process by which skin or other body tissue repairs itself after trauma. In undamaged skin, the epidermis (surface layer) and dermis (the deeper layer) form a protective barrier against the external environment. When the barrier is broken, an orchestrated cascade of biochemical events is set into motion to repair the damage. This process is divided into predictable phases: hemostasis (blood clotting), inflammation, tissue growth and proliferation, and tissue remodeling or maturation.

The wound healing process is both complex and fragile, and it is susceptible to interruption or failure, leading to the formation of non-healing chronic wounds. Factors that contribute to non-healing chronic wounds are diabetes, venous or arterial disease, infection, and metabolic deficiencies of old age.

Advancements in the clinical understanding of wounds and their pathophysiology have commanded significant biomedical innovations in the treatment of acute, chronic, and other types of wounds. Many biologics, skin substitutes, bio-membranes, and scaffolds have been developed to facilitate wound healing through various mechanisms (2). Wound healing is a complex and dynamic process of restoring cellular structure and tissue layers. Future advances in wound healing will focus on the agents that influence the repair of damaged tissue. This may include laser techniques, stem cells, fetal tissue, and other modalities that enhance the proliferation and migration of cells, and acceleration of the healing process (3).BioXyTran Inc.’s product BXT-252 can improve the supply of oxygen to wounded tissue and potentially accelerate healing. It can be applied together with any of the above treatment modalities.

(2) Vyas KS, Vasconez HC. Wound Healing: Biologics, Skin Substitutes, Biomembranes and Scaffolds. Healthcare. 2014; 2(3): 356-400
(3) The 2015 Physician’s Guide to the Wound Institute®

Corporate Governance

Bioxytran, Inc. is committed to the maintenance of high ethical standards in its dealings with all those with whom it is involved. This is reinforced by our company’s strong belief in integrity, named as one of Bioxytran, Inc’s Corporate Values. This Code of Ethics has been adopted by our Board of Directors and summarizes the standards that must guide our actions. All employees, including our officers and directors, are required to read this policy carefully and to adhere to its principles and spirit in the daily execution of their tasks and responsibilities.

Code of Ethics

Charter for the Audit Committee of the Board of Directors

The purpose of the Audit Committee is to assist the Board of Directors in fulfilling its oversight responsibilities for the financial reporting process, reviewing the systems of internal controls which management and the Board have established, appointing, retaining and overseeing the performance of independent accountants, overseeing the Company’s accounting and financial reporting processes and the audits of the Company’s financial statements and monitoring compliance with laws and regulations and the Company’s Code of Business Conduct. However, the Committee’s function is one of oversight only and shall not relieve the Company’s management of its responsibilities for preparing financial statements which accurately and fairly present the Company’s financial results and condition, or the responsibilities of the independent accountants relating to the audit or review of financial statements.